Peanut IgE Test

If you or your child has ever broken out in hives after eating peanuts, or if eczema and egg allergy put your infant in a higher risk category, this test answers the question that matters most: is the immune system actually armed to react? Peanut IgE (immunoglobulin E) measures the specific antibodies your body has made against peanut proteins. A detectable level means your immune system has "noticed" peanut and built a response. But that response does not always translate into a real allergic reaction.

This distinction between sensitization (having the antibodies) and true clinical allergy (having symptoms when you eat peanut) is the single most important thing to understand about this test. Many people, especially children, test positive for peanut IgE yet eat peanuts without any problem. A positive result is the start of a conversation, not a diagnosis by itself.

Sensitization vs. True Allergy

Your immune system can produce IgE antibodies against peanut proteins without ever causing you harm. In large studies of children, a substantial fraction of those with detectable peanut IgE above the standard sensitization threshold of 0.35 kUA/L (a unit measuring very small antibody concentrations) tolerate peanut just fine. A meta-analysis pooling data across multiple diagnostic studies found that whole peanut IgE and skin prick testing are good at catching people who are sensitized, but they often flag people who are not actually allergic.

This is where component testing adds real value. Peanut contains several proteins, and your immune system may react to some but not others. The protein called Ara h 2 is the strongest predictor of true clinical allergy. In infants screened before their first peanut exposure, Ara h 2 IgE at a cutoff of just 0.1 kUA/L caught 94% of truly allergic infants while correctly clearing 98% of tolerant ones. Whole peanut IgE at the same cutoff caught every allergic infant but incorrectly flagged about 22% of tolerant ones. If your lab offers Ara h 2 testing alongside whole peanut IgE, the combination gives a much sharper picture.

What Your Number Means

Peanut IgE is reported in kUA/L. There is no single cutoff that perfectly separates "allergic" from "not allergic," but research has established useful tiers for interpreting your result. Keep in mind that these thresholds come from studies using the ImmunoCAP assay platform. Your lab may use a different method, and numbers are not always directly comparable across platforms.

These ranges are drawn from pediatric cohorts and may not apply identically to adults. Your own lab will report its own reference intervals. The most meaningful comparison is always your own values over time, measured by the same lab.

The Ara h 2 Advantage

Across multiple systematic reviews and meta-analyses, Ara h 2 IgE consistently outperforms whole peanut IgE for confirming true allergy. At a cutoff of 0.35 kU/L, Ara h 2 achieves roughly 83% sensitivity and 84% specificity. At higher cutoffs, specificity climbs further. In one study of 100 children, an Ara h 2 cutoff of 1.63 kU/L reached 100% specificity, meaning every child above that level was truly allergic.

Other peanut components (Ara h 1, Ara h 3, Ara h 6) add modest information. Ara h 8 and Ara h 9 IgE can be misleading because they reflect cross-reactivity with birch pollen or other plant proteins rather than genuine peanut allergy. If you live in a region with high birch pollen counts and test positive for peanut IgE, some of that signal may be coming from cross-reactive antibodies rather than true peanut sensitization. Ara h 2 cuts through this noise.

Reaction Risk and Severity

Higher peanut IgE levels are linked to a greater chance of reacting during supervised oral food challenges, lower doses that trigger reactions, and a higher risk of severe reactions including anaphylaxis (a serious whole-body allergic response). In a large dataset of over 2,200 food challenges across multiple allergens, the risk of anaphylaxis rose across IgE levels, with those in the highest third of IgE values roughly 2.7 times as likely to have anaphylaxis as those in the lowest third.

That said, the relationship is statistical, not absolute. Some people with very high peanut IgE have mild reactions, and some with modest levels react severely. A rapid evidence review found that IgE sensitization alone is not a reliable standalone predictor of how bad a future reaction will be. Other factors like asthma, age, and how quickly treatment is given also shape severity. This is why allergists use peanut IgE to estimate probability, not to make guarantees.

Natural Resolution in Children

Peanut allergy is often assumed to be lifelong, but about one third of infants diagnosed with peanut allergy in one population cohort had outgrown it by age 10. The strongest signals of resolution were a declining Ara h 2 IgE trajectory over childhood and a rising ratio of peanut-specific IgG4 (a "blocking" antibody that competes with IgE) to peanut IgE. No single early measurement reliably predicted who would resolve, but the trend over serial readings was informative.

This finding has practical implications for anyone managing a child's peanut allergy. A level that was high at age 2 may look very different at age 6 or 10. Retesting periodically, rather than assuming the diagnosis is permanent, gives you the data you need to decide when to pursue a supervised food challenge.

Tracking Your Trend

A single peanut IgE result is a snapshot. The real diagnostic power comes from watching how your number moves. If your child's peanut IgE has been falling steadily over two or three years, that trajectory is a stronger signal than any single reading. If you are undergoing peanut immunotherapy, serial testing shows whether your immune system is responding.

Get a baseline reading when the question of peanut allergy first comes up. If you are making no changes (no immunotherapy, no intentional exposure), retest annually. If you are undergoing treatment or introducing peanut to a high-risk infant, your allergist will likely check more often, typically every 3 to 6 months during active treatment. Always use the same lab and assay platform so your numbers are directly comparable.

When Results Can Be Misleading

Your total IgE level can inflate your peanut-specific number. In a study of over 500 children, peanut IgE tracked closely with total IgE (a moderate to strong correlation of about 0.66), meaning that someone with generally high IgE across the board may show an elevated peanut IgE that does not reflect genuine peanut-specific sensitization. If your total IgE is very high, your allergist should interpret peanut IgE as a ratio of peanut-specific IgE to total IgE for a more accurate picture.

Assay platform matters. The most widely studied cutoffs come from the ImmunoCAP system. Multiplex platforms (which test many allergens at once from a single sample) use different antibody capture methods and may give different numbers for the same blood sample. One study found correlations between platforms ranging from moderate to strong (0.56 to 0.94 depending on the component), but the numbers are not interchangeable. If you switch labs or platforms, treat the new result as a fresh baseline rather than comparing it directly to an older number.

• Cross-reactive proteins: IgE to Ara h 8 (a birch pollen cross-reactive protein) can make your whole peanut IgE look higher than your true peanut-allergy risk warrants. Ara h 2 testing sidesteps this issue.
• Recent allergic reactions: An acute allergic episode can temporarily shift IgE levels. Retest after at least 4 to 6 weeks of baseline stability for the most representative reading.
• Age and geography: Sensitization patterns differ by age and region. Children tend to show IgE to storage proteins (Ara h 1, 2, 3) while adults in some European populations may show more cross-reactive patterns. The same number can carry different meaning in different clinical contexts.

What to Do With Your Results

A negative result (below 0.35 kUA/L) is reassuring. Peanut allergy is very unlikely, though a small number of truly allergic people can have IgE below this threshold. If your clinical suspicion remains high despite a negative result, a basophil activation test (a lab test that checks whether your allergy-related white blood cells react to peanut extract in a tube) or supervised food challenge may be the next step.

A clearly elevated result (15 kUA/L or higher), combined with a convincing history of reactions to peanut, is usually sufficient for a clinical diagnosis without needing a food challenge. The higher the number and the more consistent the reaction history, the more confident the diagnosis.

The gray zone is the middle range, roughly 0.35 to 15 kUA/L, where the test says "sensitized" but cannot tell you whether that sensitization will cause symptoms. This is where Ara h 2 component testing, and sometimes a supervised oral food challenge conducted by an allergist, become essential. If your result falls here, the most productive next step is to get Ara h 2 IgE tested (if not already done), share your results with an allergist, and discuss whether a food challenge is appropriate. Do not assume that a positive number in this range means lifelong avoidance is necessary.